”) (a subsidiary which the Company holding 70.0%) by increasing the registered capital in the amount of Baht 15,431,700, from Baht 40,000,000 to Baht 55,431,700 by issuing 154,317 new ordinary shares with
another Baht 320.00 million for phase 2-4, that source of fund from increasing in capital from the Company Baht 150.00 million, from exsisting share holders of GS Baht 50.00 million and capital increase
medicines, expanding various product types, increasing revenue and reducing costs Agenda 4 To consider and approve the issuance and offering of debentures in an amount not exceeding 300 million Baht. The
) Earnings per share (Baht) 0.03 0.04 (25.0) 0.05 (40.0) 0.15 0.20 (25.0) The company and its subsidiaries’ the operation had net profits on the fourth quarter of 2017 amounted of Baht 729.6 million, increased
reduction of cost of inventories to the net realisable value which is shown as a part of cost of sales by increasing the cost of sales. 2019 2018 Increase (decrease) Million Baht % Million Baht % Million Baht
expenses 6.73 0.30% 4.88 0.27% 1.85 37.91 Share of losses from associates 0.27 0.01% 0.00 0.00% 0.27 100.00 Income tax 20.77 0.94% 26.23 1.43% -5.46 -20.82 Net profit 43.95 1.98% 113.72 6.21% -69.77 -61.35
quarter of 2018 was decreased from 26% to 22%. This is because product/service cost mix changed, with the proportion of cost of non-mobile top-up service increasing. Expenses and expenses to revenues from
was due to the weakening Thai baht against the US dollar and Euro in the period, which resulted in THB sales increasing by Bt93 million (Table 1). The increase in revenue in 1Q20 was due mainly to an
84.20 376.72 (292.52) -347.42% 1,482.63 1,825.67 (343.03) -23.14% SHAREHOLDERS' EQUITY Issued and paid-up share capital 1,316.25 1,316.25 - 0.00% Premium on ordinary shares 264.33 264.33 - 0.00% Surplus